BMX-001 is feasible during head and neck chemoradiotherapy, but radioprotection remains unproven

In 29 patients receiving BMX-001 with head and neck chemoradiotherapy, 41.4% developed grade 3 mucositis, without a randomized comparator.

KEY POINTS

  • This multicenter phase I/II trial (NCT02990468) evaluated BMX-001, a manganese metalloporphyrin superoxide dismutase mimic, during cisplatin-based chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Twenty-nine patients were enrolled at three US institutions between May 2017 and December 2019. Most had oropharyngeal cancer (25/29, 86.2%), including 24 HPV-positive cases, and 26 patients (89.7%) received definitive rather than postoperative chemoradiotherapy.
  • BMX-001 was administered subcutaneously throughout chemoradiotherapy. Six patients received lower dose levels, while 23 received the recommended phase II regimen of a 28-mg loading dose followed by 14 mg twice weekly. Definitive IMRT delivered 69.3–70 Gy in 33–35 fractions, while postoperative treatment delivered 60–66 Gy in 30–33 fractions, with concurrent weekly or three-weekly cisplatin. The study was originally designed to enroll up to 48 patients but stopped after 29 because of slow recruitment and expiration of funding.
  • No protocol-defined dose-limiting toxicity occurred among 28 patients with complete safety follow-up. All patients experienced grade 1 injection-site reactions. One patient developed two grade 3 adverse events considered possibly related to BMX-001, consisting of fever with pancytopenia and hyponatremia. Among patients receiving the recommended phase II dose, 82.6% completed all planned BMX-001 administrations.
  • Severe oral mucositis remained common despite BMX-001 administration. Grade 3 oral mucositis occurred in 12/29 patients (41.4%), with no grade 4 events. Median onset of severe mucositis was 43 days after treatment initiation, and median duration was 25 days. Most severe episodes (83.3%) resolved within five weeks after chemoradiotherapy. Without a control group receiving chemoradiotherapy alone, these rates cannot establish whether BMX-001 reduced mucositis incidence, severity, or duration.
  • Clinician-reported xerostomia and dermatitis rates were relatively low, but salivary function remained impaired. Acute grade ≥2 xerostomia occurred in 5 patients (17.9%), while chronic grade ≥2 xerostomia occurred in 2 patients (9.1%). Grade 3 dermatitis affected 2/29 patients (6.9%). Median unstimulated salivary flow declined from 0.56 g/min at baseline to 0.22 g/min at 12 months, while stimulated flow decreased from 1.28 to 0.70 g/min.
  • Quality-of-life measurements showed post-treatment recovery but persistent dry-mouth symptoms. Among 23 patients treated at the recommended phase II dose, model-estimated FACT-HN scores decreased from 123.6 at baseline to 99.4 at treatment completion, a change of −24.1 points (p<0.001). Scores were no longer significantly different from baseline at six months. However, patient-reported dry-mouth severity remained elevated at 12 months (+1.21 points, 95% CI 0.57–1.85). Questionnaire completion at 12 months was only approximately 59–66%, limiting interpretation of longer-term recovery.
  • Oncological outcomes were encouraging but cannot establish tumor safety or treatment efficacy. At a median follow-up of 24 months, all patients were alive, and 28/29 (96.6%) had not developed progression; one patient experienced distant pulmonary metastases. However, the cohort predominantly comprised HPV-positive oropharyngeal cancer patients with favorable prognostic characteristics. The absence of randomization, heterogeneous treatment schedules, and early termination prevent conclusions that BMX-001 improves toxicity outcomes or preserves tumor control compared with standard chemoradiotherapy.

CLINICAL TAKEAWAY

BMX-001 could be administered alongside cisplatin-based head and neck chemoradiotherapy with acceptable initial tolerability, but severe mucositis remained frequent and persistent xerostomia was observed. The uncontrolled phase I/II design does not demonstrate that BMX-001 prevents radiation toxicity or preserves oncological efficacy. Randomized trials are required to establish its clinical value.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction